Tests eplerenone effects on the heart in primary aldosteronism
Tests eplerenone, which blocks aldosterone, in adults with primary aldosteronism and high blood pressure.
Plain-language title generated from the registry record
Registry title: Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
Key facts
- Where
- Boston, United StatesSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT05030545, who can take part
Where in United States
- Brigham and Women's HospitalBoston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Brigham and Women's Hospital
- Trial code
- NCT05030545
- Record updated
- 15 October 2026
- Original description
This research study aims to learn more about the impact the hormone aldosterone on the heart. Primary aldosteronism is a condition where the body's adrenal glands make too much of the hormone aldosterone, which can cause high blood pressure and increase the risk of heart and kidney disease. Treatment with medications that block aldosterone can reduce that risk. This study is trying to learn whether treatment with a medication that blocks aldosterone can improve heart function in people who make too much aldosterone.Read full original descriptionShow less
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
This research study aims to learn more about the impact the hormone aldosterone on the heart. Primary aldosteronism is a condition where the body's adrenal glands make too much of the hormone aldosterone, which can cause high blood pressure and increase the risk of heart and kidney disease. Treatment with medications that block aldosterone can reduce that risk. This study is trying to learn whether treatment with a medication that blocks aldosterone can improve heart function in people who make too much aldosterone.
Inclusion: Adults aged 18-85; Able to provide informed consent and willing to comply with the study; Able to fit safely in PET/CT scanner (weight limit 500 pounds; diameter and circumference of PET/CT scanner are 70 cm and 220 cm, respectively); Hypertension treated with at least one antihypertensive drug; Cohort A: Clinically confirmed diagnosis of PA not yet treated with mineralocorticoid receptor antagonists; Adults aged 18-85; Able to provide informed consent and willing to comply with the study; Able to fit safely in PET/CT scanner (weight limit 500 pounds; diameter and circumference of PET/CT scanner are 70 cm and 220 cm, respectively); Hypertension treated with at least one antihypertensive drug; Cohort B: Clinically indicated cardiac PET perfusion scan within the preceding 3 months and echocardiogram within the preceding 6 months.
Exclusion: History of MI, CABG, known cardiomyopathy (EF <40%, hypertrophic cardiomyopathy, and/or amyloid), cardiac transplantation; Contraindication or allergy to eplerenone or spironolactone; History of MI, CABG, known cardiomyopathy (EF <40%, hypertrophic cardiomyopathy, and/or amyloid), cardiac transplantation; Contraindication or allergy to eplerenone or spironolactone; eGFR < 45 mL/min/1.73m2 or potassium > 5.1 on labs within the preceding 3 months; eGFR < 45 mL/min/1.73m2 or potassium > 5.1 on labs within the preceding 3 months; Current pregnancy or breastfeeding; Cohort A: Planned adrenalectomy in the subsequent 6 months; Cohort B: Subclinical \& Undiagnosed PA; Current pregnancy or breastfeeding; Cohort B: 10% or greater burden of ischemia on qualifying PET; Cohort B: Planned coronary angiogram/revascularization in the subsequent 6 months.
Cohort A: Overt \& Diagnosed PA.